Skip to main content

Table 3 Clinical outcomes

From: High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention

  NPR on aspirin (n = 1240) HPR on aspirin (n = 91) P value NPR on clopidogrel (n = 891) HPR on clopidogrel (n = 437) P value
In hospital
 Definite/probable Stent thrombosis 1 0 NS 0 1 0.329
 All cause death 0 0 NS 0 0 NS
 Cardiac death 0 0 NS 0 0 NS
 Spontaneous MI 2 0 NS 0 2 0.108
 TLR 1 0 NS 0 1 0.329
 TVR 1 0 NS 0 1 0.329
 Ischemic stroke 8 (0.6) 0 NS 4 (0.4) 4 (0.9) 0.451
 All bleeding 39 (3.1) 3 (3.3) 0.762 30 (3.4) 12 (2.7) 0.619
 Hemorrhagic stroke 3 (0.2) 0 NS 3 (0.3) 0 0.555
 MACCE 10 (0.8) 0 NS 4 (0.5) 6 (1.4) 0.090
At 1 years
 Definite/probable Stent thrombosis 3 (0.2) 8 (8.8) < 0.001 1 (0.1) 10 (2.3) < 0.001
 All cause death 8 (0.6) 2 (2.2) 0.146 3 (0.3) 7 (1.6) 0.018
 Cardiac death 2 (0.2) 2 (2.2) 0.025 1 (0.1) 3 (0.7) 0.107
 Spontaneous MI 17 (1.4) 3 (3.3) 0.152 10 (1.1) 10 (2.3) 0.147
 TLR 30 (2.4) 0 (0) 0.260 25 (2.8) 5 (1.1) 0.075
 TVR 31 (2.5) 0 (0) 0.265 25 (2.8) 6 (1.4) 0.123
 Ischemic stroke 9 (0.7) 1 (1.1) 0.509 9 (1.0) 1 (0.2) 0.180
 All bleeding 64 (5.2) 3 (3.3) 0.619 48 (5.4) 19 (4.3) 0.505
 Hemorrhagic stroke 5 (0.4) 0 NS 3 (0.3) 2 (0.5) 0.666
 MACCE 40 (3.2) 5 (5.5) 0.228 30 (3.4) 15 (3.4) 0.951
At 2 years
 Definite/probable Stent thrombosis 5 (0.4) 9 (9.9) < 0.001 1 (0.1) 13 (3.0) < 0.001
 All cause death 20 (1.6) 7 (7.7) 0.002 3 (0.3) 23 (5.3) < 0.001
 Cardiac death 4 (0.3) 7 (7.7) < 0.001 1 (0.1) 10 (2.3) < 0.001
 Spontaneous MI 23 (1.9) 9 (9.9) < 0.001 11 (1.2) 21 (4.8) < 0.001
 TLR 60 (4.8) 5 (5.5) 0.799 51 (5.7) 14 (3.2) 0.057
 TVR 65 (5.2) 5 (5.5) 0.809 51 (5.7) 19 (4.3) 0.360
 Ischemic stroke 16 (1.3) 2 (2.2) 0.352 12 (1.3) 6 (1.4) NS
 All bleeding 118 (10.0) 8 (9.2) NS 93 (10.9) 33 (7.9) 0.110
 Hemorrhagic stroke 8 (0.6) 0 (0) NS 4 (0.4) 4 (0.9) 0.451
 MACCE 106 (8.5) 15 (16.5) 0.021 66 (7.4) 54 (12.4) 0.004
  1. MI myocardial infarction, TLR target lesion revascularization, TVR target vessel revascularization, MACCE adverse cardiovascular and cerebrovascular events, NPR normal platelet reactivity, HPR high platelet reactivity